jamunjar-logo
whatsapp
cartmembermenu
Search for
"test & packages"
"physiotherapy"
"heart"
"lungs"
"diabetes"
"kidney"
"liver"
"cancer"
"thyroid"
"bones"
"fever"
"vitamin"
"iron"
"HTN"

Hysterectomy Biopsy - XL

Biopsy
image

Report in 288Hrs

image

At Home

nofastingrequire

No Fasting Required

Details

Uterus & adnexa histopathology.

₹888₹1,269

30% OFF

Hysterectomy Biopsy - XL

  • Why is it done?
    • Histopathological examination of uterine tissue obtained during hysterectomy to identify benign and malignant conditions
    • Diagnosis of endometrial cancer, uterine sarcoma, and other malignancies affecting the uterus
    • Evaluation of abnormal uterine bleeding, chronic pelvic pain, or abnormal imaging findings
    • Assessment of uterine fibroids (leiomyomas), adenomyosis, and endometrial polyps
    • Performed following surgical removal of the uterus for various gynecologic indications
    • Determining tumor grade, stage, and extent of invasion in cancer cases
  • Normal Range
    • Normal findings include benign endometrial tissue with appropriate glandular and stromal components consistent with the patient's age and menopausal status
    • Absence of malignancy: Reported as 'No evidence of malignancy' or 'Benign' pathology
    • Benign smooth muscle: Normal myometrium composed of smooth muscle fibers organized in interlacing bundles
    • Atrophic or secretory endometrium depending on hormonal status
    • Result interpretation: Results are reported qualitatively as presence or absence of pathologic findings rather than numeric values
    • Report format includes detailed description of tissue composition, cellular characteristics, and any notable findings
  • Interpretation
    • Malignant Findings: Presence of adenocarcinoma (endometrioid, serous, clear cell, or mixed types); diagnosis of uterine sarcoma; presence of metastatic disease; indicates need for staging studies and oncologic management
    • Hyperplastic Changes: Simple or complex hyperplasia with or without atypia; indicates increased risk of progression to malignancy
    • Inflammatory Conditions: Endometritis, chronic inflammation, or evidence of infection; may explain abnormal bleeding symptoms
    • Benign Conditions: Leiomyomas (fibroids), adenomyosis, polyps, or cysts; benign but may contribute to symptoms
    • Tumor Grading and Staging: Grade 1-3 assessment; depth of myometrial invasion documented; lymphovascular invasion noted; determines treatment decisions and prognosis
    • Special Stains and Immunohistochemistry: Additional testing for tumor characterization, hormone receptor status, and mismatch repair protein assessment
    • Factors Affecting Results: Menstrual cycle phase; hormonal therapy; previous radiation; specimen fixation and preparation; tumor heterogeneity
  • Associated Organs
    • Primary Organ: Uterus (including endometrium, myometrium, and serosa)
    • Endometrial Cancer: Most common gynecologic malignancy; risks include obesity, diabetes, hypertension, and estrogen exposure
    • Uterine Sarcoma: Malignant smooth muscle or stromal tumors; more aggressive than carcinomas; require different treatment approach
    • Adenomyosis: Benign condition causing abnormal uterine bleeding and pelvic pain
    • Leiomyomas (Fibroids): Benign smooth muscle tumors; common indication for hysterectomy
    • Endometrial Polyps: Benign growths; small risk of malignant transformation
    • Complications of Malignancy: Metastatic spread to ovaries, fallopian tubes, peritoneum, and distant organs; vaginal bleeding and infection; uterine perforation
  • Follow-up Tests
    • If Malignancy Detected:
    • Staging imaging (CT chest/abdomen/pelvis or MRI); CA-125 tumor marker level; pelvic lymph node assessment; molecular testing for MMR status and microsatellite instability
    • For Endometrial Hyperplasia:
    • Hormone level assessment (estrogen, progesterone); repeat endometrial biopsy if atypia present; metabolic screening (glucose, lipids); gynecologic follow-up every 6-12 months
    • For Inflammatory Findings:
    • Infection workup (cultures, PCR); CBC with differential; inflammatory markers (ESR, CRP); consideration of antimicrobial therapy
    • Complementary Testing:
    • Pap smear for cervical screening; HPV testing if indicated; pelvic ultrasound for residual pathology assessment; serum tumor markers monitoring in cancer cases
    • Monitoring and Surveillance:
    • Post-operative follow-up at 2-4 weeks; oncology referral for cancer cases; adjuvant therapy planning (radiation, chemotherapy); regular gynecologic assessment for recurrence monitoring
  • Fasting Required?
    • Fasting: No
    • This is a surgical pathology test performed on tissue obtained during hysterectomy procedure; fasting requirements depend on the surgical procedure itself, not the biopsy
    • Pre-Operative Requirements:
    • NPO (nothing by mouth) from midnight before surgery; follow anesthesia-specific fasting guidelines (typically 6-8 hours for food, 2 hours for clear liquids)
    • Medication Instructions:
    • Continue routine medications as directed by surgeon; may hold anticoagulants and antiplatelet agents per surgical protocol; discuss all medications with surgical team
    • Special Preparation:
    • Bowel preparation if indicated; vaginal cleansing as directed; remove all jewelry, makeup, and nail polish; arrange transportation; sign informed consent; complete pre-operative assessment and lab work

How our test process works!

customers
customers